NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first...
First-in-class agent targets WISP1 in patients with IPF
Primary endpoint in WISPer trial is change in Forced Vital Capacity (FVC) at 24 Weeks
BOSTON, June 5,...